An improved financial position produced healthy gains for a biopharma stock Thursday. Here’s some small stocks making big moves on Thursday, March 21, 2019 (as of 4 pm EST):
Crescita Therapeutics Inc. (TSX:CTX), a biopharma stock, powered 31% higher to $0.67 on Thursday after announcing that its fiscal 2018 revenue rose 38% to $16.6 million, while its Adjusted EBITDA of $1.5 million was a $5.9 million improvement from 2017.
As well, shares of Neovasc Inc. (TSX:NVCN) added 2% at $0.63 as the developer of minimally-invasive devices for the treatment of refractory angina said the Higher Regional Court in Munich, Germany has dismissed the case brought by Edwards Lifesciences CardiAQ LLC against Neovasc in Germany.
Marifil Mines Limited (TSXV:MFM), meanwhile, reported that it has begun work for a mineral resource estimation for the Company’s San Roque property in Argentina. Marifil Mines stock moved up 64% to $0.115 following the announcement.
Finally, Jiulian Resources Inc. (TSXV:JLR) shares gained 5% to $0.105 after the junior explorer announced that it is expanding its Phase I maiden drill program at its wholly-owned Big Kidd Project in British Columbia.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Crescita Therapeutics Inc. (TSX:CTX), a biopharma stock, powered 31% higher to $0.67 on Thursday after announcing that its fiscal 2018 revenue rose 38% to $16.6 million, while its Adjusted EBITDA of $1.5 million was a $5.9 million improvement from 2017.
